Story
Legend Biotech Stock Slides Despite First-Ever Profit and Earnings Beat

Legend Biotech (NASDAQ: LEGN) shares fell 2.4% in pre-market trading despite the company reporting its first quarter of company-wide profitability and beating analyst expectations for the second quarter of 2026. The decline illustrates a classic "sell the news" dynamic, where strong results were overshadowed by mounting analyst concerns and recent leadership changes.
Strong Quarter Meets Muted Reception
Legend Biotech announced a significant financial milestone, achieving its first-ever profitable quarter. The company posted an adjusted earnings per share (EPS) of $0.16, more than double the Wall Street consensus estimate of $0.07. Revenue also surpassed expectations, coming in at $387.5 million against a forecast of $362.81 million.
Despite the strong performance, the stock's muted reaction suggests the positive results may have already been priced in by investors following a significant run-up from its 52-week low. The selling pressure indicates that forward-looking concerns are currently outweighing the reported historical performance.
Analyst Downgrades and Competitive Headwinds
AdAdding to the selling pressure, Oppenheimer recently downgraded Legend Biotech stock to Perform from Outperform, slashing its price target to $40 from $75, according to Investing.com. This move followed a series of cautious actions from other analysts in recent weeks.
Both UBS and JPMorgan previously cited growing competitive threats to CARVYKTI, the company's key CAR-T therapy, and a lack of clear near-term positive catalysts for the stock. Investor sentiment has also been unsettled by a leadership vacuum following the CEO's departure in late July, adding another layer of uncertainty.
Company-Specific Pressure
The weakness in Legend Biotech shares was specific to the company, not a reflection of broader market trends. During the same pre-market session, the S&P 500 and Nasdaq were trading higher. This divergence highlights that investors are focused on the combination of the high-profile analyst downgrade, unresolved leadership questions, and the competitive outlook for CARVYKTI.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.